Detection of biomarkers in a rapid and highly sensitive manner
New point-of-care diagnostic devices are being developed and innovated to match the rapid progress in the field of medical science. As the biological species are evolving day by day due to various natural factors, it has given birth to new diseases. Some are critical and incurable but some can be treated with early detection. So, to help patients with such diseases, it’s important to have easy access to the biomarkers that can help in the identification and diagnosis of the disease.
As a disease attacks a person, physiological transmissions that are responsible to determine the biological state of the person change in response to the status of the disease. A biomarker is one such characteristic that is mainly calculated and evaluated to check the normality of normal body activities. Any pharmacologic response, pathogenic processes, therapeutic assessment or any indicator that measures the risk or the sign of any disease can be a biomarker.
Biomarkers play an important part in the detection, treatment and follow-up of diseases. It is necessary to remember that diseases treated in the early-stage results have the highest probability of success. But, due to some technical deficiencies in current technologies to make biomarkers, the potential of biomarkers is not completely explored. Therefore, the developments in technologies that can make accurate detection of diseases possible at an early stage with experimental and simple protocols are highly recognized. With these new advancements, it also became important to test the progress through several sensitive assays. So, there should not be any error that could result in mixed results for the consumers and can endanger their life.
The main reason to choose biomarkers is to diagnose illness and to make reliable and reasonable devices for the easy treatment of diseases and disorders. By including biomarker detection technologies, medics can pick more accurate care for their patients. Adding on, it can also help doctors to monitor the diseases’ symptoms, progression, and recurrence and design the treatment in that manner. When it comes to the sensitive test, it becomes equally important to nullify all the misconceptions about specificity, sensitivity, and predictive values.
Diagnostic tests depend on a few quantitative biomarkers. The two important metrics used to understand the quality of a test are test sensitivity and specificity. The readings of disease status are based upon the test results and are also helpful in research for medics and public health management.
Sensitivity is the smallest value of analyte in the assay buffer where the assay can analytically differentiate from the background. It is a computed value that is decided by comparing readings from many samples of low standard concentrations and zero concentrations. These tests include ΔAbs/Δ concentration to measure the sensitive values. Sometimes, assay sensitivity can be higher than the smallest standard point. They are widely used in the development and invention of medicines to cure diseases and find the suitable cure to eliminate them. Sensitivity can be defined as an ability to authorise an individual with any positive disease. The specification of any test is its capability to identify an individual who does not have a negative disease.
If you're looking for a trusted and proven sensitive assay service, then AgPlus diagnostics is the best choice. We have worked with our experienced sensitive assay development team, and we take pride in launching the Agilis Reader. This intelligent pairing fills the gap in the market requirement for an ultra-sensitive, rapid and fully quantitative point of care test to be used for a wide range of non-clinical and clinical applications. Feel free to contact AgPlus Diagnostics for any kind of point of care blood testing technologies.














